Financial Statements

Bayer Group Consolidated Income Statements

	3rd Quarter 2008	3rd Quarter 2009	First Nine Months 2008	First Nine Months 2009
	€ million	€ million	€ million	€ million
Net sales	7,948	7,392	24,995	23,296
Cost of goods sold	(4,076)	(3,579)	(12,435)	(11,159)
Gross profit	3,872	3,813	12,560	12,137

Selling expenses	(2,017)	(1,880)	(5,953)	(5,873)
Research and development expenses	(662)	(692)	(1,943)	(2,012)
General administration expenses	(417)	(404)	(1,275)	(1,210)
Other operating income	214	172	1,064	718
Other operating expenses	(306)	(363)	(1,321)	(1,120)
Operating result [EBIT]	684	646	3,132	2,640

Equity-method loss	(11)	(10)	(34)	(36)
Non-operating income	87	158	376	636
Non-operating expenses	(352)	(410)	(1,155)	(1,488)
Non-operating result	(276)	(262)	(813)	(888)

Income before income taxes	408	384	2,319	1,752

Income taxes	(133)	(135)	(701)	(549)

Income from continuing operations after taxes	275	249	1,618	1,203

Income from discontinued operations after taxes	3	0	3	0

Income after taxes	278	249	1,621	1,203
of which attributable to non-controlling interest	1	0	8	(3)
of which attributable to Bayer AG stockholders (net income)	277	249	1,613	1,206

	€	€	€	€
Earnings per share

From continuing operations
Basic*	0.37	0.30	2.06	1.52
Diluted*	0.37	0.30	2.06	1.52

From discontinued operations
Basic*	0.00	0.00	0.00	0.00
Diluted*	0.00	0.00	0.00	0.00

From continuing and discontinued operations
Basic*	0.37	0.30	2.06	1.52
Diluted*	0.37	0.30	2.06	1.52
* The ordinary shares that resulted from conversion of the mandatory convertible bond were treated as already issued shares since the issuance of the bond.